Chief Financial Officer · Arcutis Biotherapeutics, Inc. (ARQT)

John Smither

A named executive officer of Arcutis Biotherapeutics in every fiscal year CompBrief holds from FY2021 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,102,418

Salary $183,333Stock awards $1,053,771

FY2021: $6,250,292

4th of 6 named executive officers at Arcutis Biotherapeutics by FY2024 total.

6 named officers on file for Arcutis Biotherapeutics, FY2024

John Smither’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 7 equity grants, each cited to its filing
  • ARQT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Arcutis Biotherapeutics’s whole pay program stands against its peers

  • Arcutis Biotherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ARQT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A).

Free

Get John Smither’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

John Smither compensation by year

Arcutis Biotherapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Arcutis Biotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2024
Salary$100,000$183,333
Bonus$0$0
Stock awards$755,233$1,053,771
Option awards$5,384,317$759,714
Non-equity incentive$0$105,600
Pension and deferred compensation$0$0
All other$10,752$0
Total$6,250,292$2,102,418

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcutis Biotherapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001787306-25-000069, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Arcutis Biotherapeutics, Inc. filed document, accession 0001787306-25-000069. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

$6.3M
$2.1M
FY21
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU100,000$1,393,000—
RSU5,357$74,623—
RSU698$9,723—
Option50,000—$8.84

Per the Outstanding Equity Awards at Fiscal Year-End table in Arcutis Biotherapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Arcutis Biotherapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
David TopperChief Financial Officer$5,311,203
Todd Franklin WatanabePresident and Chief Executive Officer$3,689,491
Patrick BurnettExecutive Vice President and Chief Medical Officer$2,513,050
John Smither · this pageChief Financial Officer$2,102,418
L. Todd EdwardsChief Commercial Officer$1,965,145
Masaru MatsudaGeneral Counsel$1,737,532

The full Arcutis Biotherapeutics compensation record

free company brief

This page is one person within Arcutis Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Arcutis Biotherapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcutis Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Smither's compensation dossier · One-time report. No refunds.